Fulvestrant Efficacy in Artificial Menopausal Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Patients under 50 Years Old

Journal Title: International Journal of Current Research and Review - Year 2018, Vol 10, Issue 6

Abstract

Introduction: This study investigated the efficacy of fulvestrant in premenopausal patients with metastatic breast cancer who developed artificial menopause using a luteinizing hormone releasing hormone analogue. Methods: This retrospective study was conducted at the Istanbul Okmeydani Education and Research Hospital. Results: A total of 37 patients were evaluated, with a median age of 39 years old (range 27–49) and a median follow-up time of 20.2 months (0–78). Of these patients, 86.5% had invasive ductal carcinoma, 5.4% had invasive lobular carcinoma. Bone metastasis was found in 83.8% of the patients, lung metastasis in 21.6%, lymph node metastasis in 16.2%, liver metastasis in 13.5%, and brain metastasis in 5.4%. The progression-free survival (PFS) was a median of 12 months after starting the fulvestrant. The PFS was relatively shorter in those with brain metastases, but there was no statistically significant difference. The median PFS was 12 months in 2 series and 8 months in 3 and later series, which was statistically significant (p=0.025). The overall survival (OS) was a median of 77 months; it was 86% at 12 months, 63% at 36 months, and 56% at 60 months. The median OS of the 2nd line was 20 months. No grade 3-4 toxic effects were observed. Conclusion: As in naturally postmenopausal patients, fulvestrant was found to be effective and tolerable in patients treated with artificial menopausal hormone receptor-positive metastatic breast cancer under the age of 50. The fulvestrant was more effective in those who did not previously receive hormonal therapy.

Authors and Affiliations

Caglayan Geredeli

Keywords

Related Articles

Forecasting of Monthly Mean Rainfall in Rayalaseema

Seasonal Autoregressive Integrated Moving Average (SARIMA) model in analyzing the forecast of monthly mean rainfall in Rayalaseema (India) using R is discussed. We have checked the different ARIMA models according to the...

A Study of Haemoglobin Level based on Tenofovir given as a First Line Anti Retroviral Therapy in Human Immune Virus Infected Patient

Background: Tenofovir has been recently introduced in our country as first line therapy in HIV infection but limited data available on safety profile & tolerability in Indian population of patients. This study focused on...

Determination of Sex Through Handwriting Characteristics

Aim: The aim of this study is to determine the gender of an individual by handwriting Methodology: In this study total 130 handwriting samples were collected and analyzed. In which 65 males and 65 female volunteers of ag...

Diagenesis of Sandstones in a Part of the Tichna Structure of Tripura Fold Belt, India

Aim: The aim of the present research work is to study the petrography and diagenesis of the sandstones in a part of the Surma Group of the Tichna field located in the western part of the Tripura Fold Belt. Methodology: T...

Myocardial Bridges as a Risk Factor for Coronary Atherosclerosis

Introduction: The presence of a myocardial bridge on the ramus interventricularis anterior can lead to myocardial ischemia and changes in the structure of the vessel wall, especially in the segment proximal to the bridge...

Download PDF file
  • EP ID EP542237
  • DOI 10.7324/IJCRR.2018.1067
  • Views 115
  • Downloads 0

How To Cite

Caglayan Geredeli (2018). Fulvestrant Efficacy in Artificial Menopausal Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Patients under 50 Years Old. International Journal of Current Research and Review, 10(6), 31-36. https://europub.co.uk/articles/-A-542237